We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 06. 01. | 장 마감 후 (AMC) | — | — | — | $410K | — | 예정 |
| FY2025 Q3 | 2025. 09. 30. | 시각 미정 | — | $-1.05 | — | — | $390K | 보고됨 |
| FY2020 Q3 | 2019. 09. 30. | 시각 미정 | — | — | — | — | $37K |
Rating & price-target changes
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 03. 31. | HC Wainwright & Co. | — | 투자의견 하향 | Buy → Neutral | — | HC Wainwright & Co.: Buy → Neutral |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
| FY2020 Q2 | 2019. 06. 30. | 시각 미정 | — | — | — | — | $37K | 보고됨 |
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics plc is in reorganization.
Stored first · Google News · Yahoo Finance (English)
Iterum Therapeutics (ITRMF) Latest Announcement & Press Release - Moomoo
Iterum Therapeutics (ITRMF) Latest Announcement & Press Release Moomoo
Iterum Therapeutics (ITRM) Holds at $0.03 as Micro-Cap Biotech Waits for Catalysts - New Listing Stocks - thelegaladvocate.com
Iterum Therapeutics (ITRM) Holds at $0.03 as Micro-Cap Biotech Waits for Catalysts - New Listing Stocks thelegaladvocate.com